Modality
Gene Editing
MOA
CDK2i
Target
RET
Pathway
DDR
Thymoma
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Aug 2026
Phase 1Current
NCT06770637
383 pts·Thymoma
2018-08→2026-08·Not yet recruiting
383 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-255mo awayPh2 Data· Thymoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2026-08-25 · 5mo away
Thymoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06770637 | Phase 1/2 | Thymoma | Not yet recr... | 383 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 |